Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 2/20 | 0.47 |
| ▸ | NPY1R | P25929 | 1/20 | 0.44 |
| ▸ | NPY2R | P49146 | 1/20 | 0.44 |
| ▸ | NPY4R | P50391 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2195736 | 0.88 | NPY1R (0.49) | OPRD1FOLH1NPY1RNPY2RNPY4R | |
| Trifluoroacetic Acid SCHEMBL2197916 | 0.86 | FOLH1 (0.62) | LTA4HOPRD1FOLH1MMENPY1R | |
| SCHEMBL8580267 | 0.85 | OPRD1 (0.63) | OPRD1 | |
| Trifluoroacetic Acid SCHEMBL28610620 | 0.84 | LTA4H (0.67) | LTA4HOPRD1MME | |
| SCHEMBL7443503 | 0.83 | ACE (0.45) | MME | |
| SCHEMBL29666997 | 0.83 | LTA4H (0.54) | LTA4HOPRD1FOLH1MMENPY1R | |
| SCHEMBL9822809 | 0.82 | FOLH1 (0.69) | LTA4HOPRD1FOLH1MMENPY1R | |
| SCHEMBL29532240 | 0.82 | FOLH1 (0.69) | LTA4HOPRD1FOLH1MMENPY1R | |
| SCHEMBL14940816 | 0.82 | FOLH1 (0.69) | LTA4HOPRD1FOLH1MMENPY1R | |
| SCHEMBL11363918 | 0.82 | OPRK1 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680263-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2014-03-25 | — | — | US | disclosed |
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | LTA4H 4098/4885OPRD1 3859/4885FOLH1 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.